The Development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates

  1. Gang Ye
  2. Joseph Gallant
  3. Jian Zheng
  4. Christopher Massey
  5. Ke Shi
  6. Wanbo Tai
  7. Abby Odle
  8. Molly Vickers
  9. Jian Shang
  10. Yushun Wan
  11. Lanying Du Dr.
  12. Hideki Aihara
  13. Stanley Perlman
  14. Aaron LeBeau  Is a corresponding author
  15. Fang Li  Is a corresponding author
  1. University of Minnesota, United States
  2. University of Iowa, United States
  3. University of Texas Medical Branch, United States
  4. Lindsley F Kimball Research Institute, United States
  5. Lindsley F Kimball Research Institute, New York Blood Center, United States

Abstract

Combating the COVID-19 pandemic requires potent and low-cost therapeutics. We identified a series of single-domain antibodies (i.e., nanobody), Nanosota-1, from a camelid nanobody phage display library. Structural data showed that Nanosota-1 bound to the oft-hidden receptor-binding domain (RBD) of SARS-CoV-2 spike protein, blocking viral receptor ACE2. The lead drug candidate possessing an Fc tag (Nanosota-1C-Fc) bound to SARS-CoV-2 RBD ~3000 times more tightly than ACE2 did and inhibited SARS-CoV-2 pseudovirus ~160 times more efficiently than ACE2 did. Administered at a single dose, Nanosota-1C-Fc demonstrated preventive and therapeutic efficacy against live SARS-CoV-2 infection in both hamster and mouse models. Unlike conventional antibodies, Nanosota-1C-Fc was produced at high yields in bacteria and had exceptional thermostability. Pharmacokinetic analysis of Nanosota-1C-Fc documented an excellent in vivo stability and a high tissue bioavailability. As effective and inexpensive drug candidates, Nanosota-1 may contribute to the battle against COVID-19.

Data availability

Coordinates and structure factors have been deposited to the Protein Data Bank with accession number 7KM5.

Article and author information

Author details

  1. Gang Ye

    Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States
    Competing interests
    Gang Ye, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6034-2174
  2. Joseph Gallant

    Pharmacology, University of Minnesota, Minneapolis, United States
    Competing interests
    Joseph Gallant, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4943-1744
  3. Jian Zheng

    Microbiology and Immunology, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  4. Christopher Massey

    Institutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch, Galveston,, United States
    Competing interests
    No competing interests declared.
  5. Ke Shi

    Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
  6. Wanbo Tai

    New York Blood Center, Lindsley F Kimball Research Institute, New York, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9864-8993
  7. Abby Odle

    Microbiology and Immunology, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  8. Molly Vickers

    Microbiology and Immunology, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  9. Jian Shang

    Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States
    Competing interests
    Jian Shang, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
  10. Yushun Wan

    Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States
    Competing interests
    Yushun Wan, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
  11. Lanying Du Dr.

    Viral Immunology Laboratory, Lindsley F Kimball Research Institute, New York Blood Center, New York, United States
    Competing interests
    No competing interests declared.
  12. Hideki Aihara

    Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7508-6230
  13. Stanley Perlman

    Microbiology and Immunology, University of Iowa, Iowa City, United States
    Competing interests
    No competing interests declared.
  14. Aaron LeBeau

    Pharmacology, University of Minnesota, Minneapolis, United States
    For correspondence
    alebeau@umn.edu
    Competing interests
    Aaron LeBeau, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
  15. Fang Li

    Veterinary and Biomedical Sciences, University of Minnesota, Saint Paul, United States
    For correspondence
    lifang@umn.edu
    Competing interests
    Fang Li, The University of Minnesota has filed a patent on Nanosota-1 drugs with F.L, G.Y., A.M.L., J.P.G., J.S., and Y.W. as inventors..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1958-366X

Funding

National Institutes of Health (R01AI157975)

  • Lanying Du Dr.
  • Stanley Perlman
  • Aaron LeBeau
  • Fang Li

National Institutes of Health (R01AI089728)

  • Fang Li

National Institutes of Health (R35GM118047)

  • Hideki Aihara

University of Minnesota

  • Fang Li

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols of the University of Texas Medical Branch (protocol number 2007072), of the New York Blood Center (protocol number 194.22), of the University of Iowa (protocol number 9051795), and of the University of Minnesota (protocol number 2009-38426A).

Copyright

© 2021, Ye et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,094
    views
  • 424
    downloads
  • 46
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Gang Ye
  2. Joseph Gallant
  3. Jian Zheng
  4. Christopher Massey
  5. Ke Shi
  6. Wanbo Tai
  7. Abby Odle
  8. Molly Vickers
  9. Jian Shang
  10. Yushun Wan
  11. Lanying Du Dr.
  12. Hideki Aihara
  13. Stanley Perlman
  14. Aaron LeBeau
  15. Fang Li
(2021)
The Development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates
eLife 10:e64815.
https://doi.org/10.7554/eLife.64815

Share this article

https://doi.org/10.7554/eLife.64815

Further reading

    1. Microbiology and Infectious Disease
    Hui Li, Jun Yang ... Bo Peng
    Research Article

    Non-inheritable antibiotic or phenotypic resistance ensures bacterial survival during antibiotic treatment. However, exogenous factors promoting phenotypic resistance are poorly defined. Here, we demonstrate that Vibrio alginolyticus are recalcitrant to killing by a broad spectrum of antibiotics under high magnesium. Functional metabolomics demonstrated that magnesium modulates fatty acid biosynthesis by increasing saturated fatty acid biosynthesis while decreasing unsaturated fatty acid production. Exogenous supplementation of unsaturated and saturated fatty acids increased and decreased bacterial susceptibility to antibiotics, respectively, confirming the role of fatty acids in antibiotic resistance. Functional lipidomics revealed that glycerophospholipid metabolism is the major metabolic pathway remodeled by magnesium, where phosphatidylethanolamine biosynthesis is reduced and phosphatidylglycerol production is increased. This process alters membrane composition, increasing membrane polarization, and decreasing permeability and fluidity, thereby reducing antibiotic uptake by V. alginolyticus. These findings suggest the presence of a previously unrecognized metabolic mechanism by which bacteria escape antibiotic killing through the use of an environmental factor.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Qian Wang, Jinxin Liu ... Qian Liu
    Research Article

    Paramyxovirus membrane fusion requires an attachment protein for receptor binding and a fusion protein for membrane fusion triggering. Nipah virus (NiV) attachment protein (G) binds to ephrinB2 or -B3 receptors, and fusion protein (F) mediates membrane fusion. NiV-F is a class I fusion protein and is activated by endosomal cleavage. The crystal structure of a soluble GCN4-decorated NiV-F shows a hexamer-of-trimer assembly. Here, we used single-molecule localization microscopy to quantify the NiV-F distribution and organization on cell and virus-like particle membranes at a nanometer precision. We found that NiV-F on biological membranes forms distinctive clusters that are independent of endosomal cleavage or expression levels. The sequestration of NiV-F into dense clusters favors membrane fusion triggering. The nano-distribution and organization of NiV-F are susceptible to mutations at the hexamer-of-trimer interface, and the putative oligomerization motif on the transmembrane domain. We also show that NiV-F nanoclusters are maintained by NiV-F–AP-2 interactions and the clathrin coat assembly. We propose that the organization of NiV-F into nanoclusters facilitates membrane fusion triggering by a mixed population of NiV-F molecules with varied degrees of cleavage and opportunities for interacting with the NiV-G/receptor complex. These observations provide insights into the in situ organization and activation mechanisms of the NiV fusion machinery.